Portfoliotracker

Puma Biotechnology, Inc.

PBYI · NASDAQGS · Healthcare Biotechnology 73/100 B

7,340 $
▼ −0,430 (−5,53 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:54
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score73 / 100 Market cap390 mil. $ P/E16,0 Forward P/E22,2 P/S1,7 P/B2,7 EV/EBITDA7,7 Dividend yield– FCF yield11,80 % EPS0,46 $ Net margin10,3 % Return on equity18,2 % Beta1,33 Debt / equity0,03
52-week range 4,80 to 11,50
3-month average volume0,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Employees
179
Country
United States
Fiscal year end
31. 12.
Data since
24. 4. 2012

Explore further

Similar companies AGIOPTCTMGNXRARE

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account